San Diego-based Viking Therapeutics marked alone as a significant competitor in the weight loss drug current market in February soon after revealing promising information from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in March